度普利尤单抗治疗特应性皮炎患者过程中眼表不良事件研究现状

Dupilumab-associated ocular adverse event in patients with atopic dermatitis

特应性皮炎是一种慢性复发性炎症性皮肤病,度普利尤单抗是一种单克隆抗体,其与细胞表面白细胞介素(IL)-4α受体结合阻断IL-4及IL-13的信号通路,治疗中到重度特应性皮炎。结膜炎及睑缘炎的发病率升高是其治疗过程中较常见的不良事件,其发生的机制尚不明确,推测可能与眼表黏膜免疫调节异常、屏障功能受损以及蠕形螨定植有关。本文就度普利尤单抗治疗特应性皮炎过程中眼表症状流行病学、临床特征以及治疗方案进行综述,分析目前该药物引起眼表不良事件研究中存在的不足,深入探索发病机制的方向以及诊治的相关注意事项。

Atopic dermatitis(AD)is a chronic,relapsing,pruritic inflammatory skin disease.Dupilumab is a monoclonal antibody that inhibits interleukin(IL)-4 and IL-13 signaling pathways through its binding to IL-4αreceptor,which has been demonstrated effective in treatment of moderate-to-severe AD.There is an increased incidence of the associated ocular adverse event in the treatment of AD,the probable mechanisms of which are likely related to abnormal mucosal immune regulation,dysfunction of the ocular barrier,and Demodex colonization.In this article,the epidemiology,clinical features,and management of dupilumab for AD were reviewed,and the shortcomings of the current researches about dupilumab-associated adverse events were analyzed,as well as further study directions in exploring etiology,mechanism,and matters needing attention in diagnosis and treatment were discussed.